Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Enrique Grande, ESMO 2019 – Advances in first-line treatment of urothelial cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 3rd 2019

Enrique Grande (MD Anderson Cancer Center) discusses evolving immunotherapy combination strategies in the first line treatment of urothelial cancer at ESMO 2019.

Questions

1. In which patients with urothelial cancer is immunotherapy indicated as first-line therapy? (0:04)
2. How can we improve response rates to immune checkpoint inhibitors in patients with urothelial cancer? (0:09)
3. Which combined treatment regimens involving immune checkpoint inhibitors appear most promising? (1:10)
4. What novel agents might be combined with immune checkpoint inhibitors to further enhance responses? (1:51)
5. What do you expect to be the next major breakthrough in urothelial cancer? (2:31)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Enrique Grande has acted as an advisor for Roche, BMS, Pfizer, Eisai, Eusa Pharma, Janssen, Astellas, Bayer, Pierre Fabre, MSD and AstraZeneca.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup